Abstract 1570
Background
Systemic chemotherapy (SC) has a negative effect on ovarian functions. The aim of this study is to investigate the effect of SC on anti-müllerian hormone (AMH) levels, antral follicle counts (AFC) and ovarian volumes (MOV) in patients with BC.
Methods
The demographic, clinical and pathological features of premenopausal breast cancer (BC) patients who were operated in the Istanbul Florence Nightingale Hospital were recorded. AMH levels, AFC and MOV measurements were performed before and after adjuvant SC in 3-month periods. The patients who did not have menstruel cycles for 6 months or longer had been classified as chemotherapy induced amenorrhea (CIA). The effects of different chemotherapy regimens on AMH, AFC and MOV in terms menstruel cycles resumption and CIA were investigated.
Results
Seventy one patients were eligible for the study, and median age of them was 38 years (ranged from 23 to 51 years). Median follow-up was 37 months (ranged from 20 to 51 months), CIA developed in 62% of patients. AMH, AFC, and MOV significantly decreased one year after SC (p < 0.0001). AMH before chemotherapy (median: 1,520 vs 0,755, p = 0.001), at the end of first year (median: 0,073 vs 0,010 ng/ml, p = 0.030) and pre-treatment AFC (median12 vs 4,50, p = 0.026) was lower in patients with CIA comparing those without CIA. In multivariate logistic regression analysis, AMH levels (OR:0.273, 95%: 0.102 – 0.733, p = 0.010) and AFC (OR: 1,180, 95% CI; 1,016-1,369, p = 0.030) before SC were the most valuable and earliest factors to predict CIA. There were no significant relationships between age of the patients (≤30vs>30 ), BMI (30vs> 30), SC regimen and number of cycles (4 vs > 4) and CIA (p > 0.05).Table:
254P muitivariet analyses with logistic regrettion for CIA
| UNIVARIET | MULTIVARIET | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | ||||||
| ER | 0,19 | 0,038 | - | 0,891 | 0,035 | 0,002 | 0,000 | - 0,111 | 0,002 |
| HER 2 | 0.80 | 0,435 | - | 2,936 | 1,130 | ||||
| ALND PERFORMED | 1,75 | 0,653 | - | 4,702 | 0,265 | ||||
| AMH-1 | 0,64 | 0,454 | - | 0,914 | 0,014 | 0,273 | 0,102 | - 0,733 | 0,010 |
| AMH-5 | 0,23 | 0,063 | - | 0,812 | 0,023 | 0,009 | 0,000 | - 0,754 | 0,037 |
| AFC-1 | 0,87 | 0,780 | - | 0,961 | 0,007 | 0,735 | 0,572 | - 0,944 | 0,016 |
| AFC-5 | 0,93 | 0,741 | - | 1,165 | 0,527 | ||||
| MOV-1 | 1,00 | 0,987 | - | 1,021 | 0,686 | ||||
| MOV-5 | 0,98 | 0,854 | - | 1,158 | 0,790 | ||||
| TAXANE/W&İTHOUTTAXANE | 0,71 | 0,267 | - | 1,910 | 0,503 | ||||
| TC/AC | 0,85 | 0,209 | - | 3,491 | 0,825 | ||||
| AGE 35 | 4,66 | 1,613 | - | 13,498 | 0,004 | ||||
| CHEMONUMBER | 0,24 | 0,080 | - | 0,766 | 0,017 | ||||
| BMI 25 | 2,57 | 0,929 | - | 7,118 | 0,069 |
Conclusions
SC significantly decreases AMH and AFC values independently of chemotherapeutic agents in patients with BC. The low AMH levels and less AFC before SC may predict CIA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
İstanbul Demiroğlu Bilim University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2686 - Clinicopathological characteristics, survival and prognostic factors of breast cancer-related microangiopathic haemolytic anemia: a multicenter study
Presenter: Marion Alhenc Gelas
Session: Poster Display session 2
Resources:
Abstract
1565 - Metabolic tumor volume by 18F-FDG PET/CT is an independent prognostic factor in metastatic breast cancer
Presenter: Heekyung Ahn
Session: Poster Display session 2
Resources:
Abstract
4498 - Patient Preferences for breast cancer treatments: A Discrete Choice Experiment from four European countries
Presenter: Thomais Konstantopoulou
Session: Poster Display session 2
Resources:
Abstract
1423 - Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study
Presenter: Diana Lüftner
Session: Poster Display session 2
Resources:
Abstract
2284 - Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype
Presenter: Hee Kyung Kim
Session: Poster Display session 2
Resources:
Abstract
4598 - Administration of chemotherapy for metastatic breast cancer near the end of life: a population registry study
Presenter: Luisa Edman Kessler
Session: Poster Display session 2
Resources:
Abstract
5706 - Prognostic value of histological growth pattern in patients operated for breast cancer liver metastases
Presenter: Ali Bohlok
Session: Poster Display session 2
Resources:
Abstract
1697 - Illness perceptions, quality of life and mood in metastatic breast cancer patients
Presenter: Isabel Domingues
Session: Poster Display session 2
Resources:
Abstract
1935 - Multidisciplinary Treatments Increases Overall Survival in Patients with Newly Diagnosed Stage IV Breast Cancer：An Analysis of 2010–2014 SEER Data
Presenter: Jian Zhang
Session: Poster Display session 2
Resources:
Abstract
3875 - Correlation of radiotherapy with the prognosis of elderly patients with hormone receptor-positive breast cancer according to immunohistochemical subtyping
Presenter: Jin Zhang
Session: Poster Display session 2
Resources:
Abstract